Comparative Pharmacology
Head-to-head clinical analysis: DOXYCHEL HYCLATE versus MECLAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCHEL HYCLATE versus MECLAN.
DOXYCHEL HYCLATE vs MECLAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA binding to the mRNA-ribosome complex.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
100 mg orally or IV every 12 hours on day 1, then 100 mg daily.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
None Documented
None Documented
Terminal elimination half-life is 18–22 hours in patients with normal renal function; prolonged to 20–30 hours in severe renal impairment. Clinical context: Allows once- or twice-daily dosing.
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Doxycycline hyclate is primarily excreted via the feces (approximately 90%) as an inactive chelated complex, with renal excretion accounting for about 10% of the dose. Biliary excretion is minimal.
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic